Samsung Medical Center

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Established: 1994-01-01

Employees: 501

Market Cap: -

Website: http://www.samsunghospital.com

Clinical Trials

Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy

Phase 2

Completed

Conditions: Gastric Adenocarcinoma

Interventions: Drug: docetaxel plus selumetinib

First Posted Date: 2015-05-19

Last Posted Date: 2019-05-20

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 25

Registration Number: NCT02448290

Locations: 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

Phase 2

Completed

Conditions: Solid Tumor

Interventions: Drug: Gefitinib

First Posted Date: 2015-05-18

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 16

Registration Number: NCT02447419

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment

Phase 2

Completed

Conditions: Advanced Gastric Adenocarcinoma

Interventions: Drug: AZD6094
Drug: Docetaxel

First Posted Date: 2015-05-18

Last Posted Date: 2019-12-30

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 2

Registration Number: NCT02447380

Locations: 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Phase 1

Completed

Conditions: Advanced Gastric Adenocarcinoma

Interventions: Drug: AZD6094
Drug: docetaxel

First Posted Date: 2015-05-18

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 7

Registration Number: NCT02447406

Locations: 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of

Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL

Phase 2

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: CHOP
Drug: fractionated ICED

First Posted Date: 2015-05-15

Last Posted Date: 2020-10-22

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 134

Registration Number: NCT02445404

Locations: 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of

A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy

Phase 2

Completed

Conditions: c-MET Positive Gastric Cancer

Interventions: Drug: crizotinib

First Posted Date: 2015-05-06

Last Posted Date: 2017-02-17

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 2

Registration Number: NCT02435108

Locations: 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of

Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2

Completed

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: nab-paclitaxel
Drug: gemcitabine

First Posted Date: 2015-04-24

Last Posted Date: 2023-02-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 111

Registration Number: NCT02426281

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of

and more 5 locations

Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma

Phase 2

Completed

Conditions: T-cell Lymphoma

Interventions: Drug: BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)

First Posted Date: 2015-04-22

Last Posted Date: 2018-09-06

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 30

Registration Number: NCT02424045

The Comparison of Efficacy Between Electromagnetic Stimulation Therapy and Electromagnetic Stimulation Therapy With Extracorporeal Biofeedback

Not Applicable

Completed

Conditions: Urinary Stress Incontinence

Interventions: Device: Electromagnetic stimulation therapy (BIOCON-2000)
Device: Electromagnetic stimulation therapy with biofeedback

First Posted Date: 2015-04-22

Last Posted Date: 2019-12-02

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 66

Registration Number: NCT02423486

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Comparison of Postoperative Outcome of Hepatectomy for Living Donors According to Three Different Incision

Completed

Conditions: Healthy Donors for Liver Transplantation

Interventions: Procedure: hepatectomy midline incision
Procedure: hepatectomy conventional incision
Procedure: hepatectomy transverse incision

First Posted Date: 2015-04-10

Last Posted Date: 2019-07-25

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 60

Registration Number: NCT02413983

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy